ML-Based Multi-Sensor Fall Risk Screening in DMD
- Sponsor
- Seoul National University Hospital
- Study ID
- NCT07015632
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 10 Years - 30 Years
- Healthy Volunteers
- Not accepted
Interventions
- Performance of the Upper Limb, Brooke Scale, grip strength test — OTHERThirty patients will be evaluated at three time points (baseline, 6 months, 12 months) using clinical assessments (PUL 2.0, Brooke Scale, grip strength), computer vision-based video analysis, and machine learning algorithms.
Study Details
This prospective observational study aims to analyze changes in upper extremity functional movement over time in children with Duchenne Muscular Dystrophy (DMD). Thirty patients will be evaluated at three time points (baseline, 6 months, 12 months) using clinical assessments (PUL 2.0, Brooke Scale, grip strength), computer vision-based video analysis, and machine learning algorithms. The goal is to improve future upper limb evaluation methods for non-ambulatory DMD patients. The study includes safety monitoring and adheres to ethical standards, ensuring patient data confidentiality and providing compensation if adverse effects occur.
Key Dates
- Start date
- Jul 18, 2024
- Status verified
- May 2025
- Primary completion
- Jul 30, 2025
- Completion
- Dec 1, 2026
Study Design
- Enrollment
- 30 participants (estimated)
Primary Outcome Measure
Performance of the upper limb module 2.0 [ Time Frame: baseline - 6 months - 12 months ]
Central Contacts
- JungHyun Kim, prof82+1088632341
Related Studies
- NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)PHASE2 · Recruiting · NS Pharma, Inc. · Aurora, Colorado
- Vasodilator and Exercise Study for DMD (VASO-REx)PHASE2 · Recruiting · University of Florida · Gainesville, Florida
- Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsPHASE2 · Recruiting · Satellos Bioscience, Inc. · Los Angeles, California
- Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)PHASE3 · Recruiting · Dyne Therapeutics · Hillsborough, North Carolina